BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30218239)

  • 1. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment.
    Rimola J; Davenport MS; Liu PS; Brown T; Marrero JA; McKenna BJ; Hussain HK
    Abdom Radiol (NY); 2019 Feb; 44(2):549-558. PubMed ID: 30218239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.
    Li J; Wang J; Lei L; Yuan G; He S
    Eur Radiol; 2019 Dec; 29(12):6519-6528. PubMed ID: 31250172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of Gadoxetate-enhanced magnetic resonance imaging and computed tomography for hepatocellular carcinoma detection and transplant eligibility assessment with explant histopathology correlation.
    Jhaveri KS; Babaei Jandaghi A; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G
    Cancer Imaging; 2023 Feb; 23(1):22. PubMed ID: 36841796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
    Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
    Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T1 mapping combined with Gd-EOB-DTPA-enhanced magnetic resonance imaging in predicting the pathologic grading of hepatocellular carcinoma.
    Chen CY; Chen J; Xia CC; Huang ZX; Song B
    J Biol Regul Homeost Agents; 2017; 31(4):1029-1036. PubMed ID: 29254310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA.
    Son J; Hwang SH; Park S; Han K; Chung YE; Choi JY; Kim MJ; Park MS
    Invest Radiol; 2019 Aug; 54(8):494-499. PubMed ID: 31094878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
    Liu HF; Xu YS; Liu Z; Che KY; Sheng Y; Ding JL; Zhang JG; Lei JQ; Xing W
    Acad Radiol; 2021 Jun; 28(6):790-798. PubMed ID: 32414638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.
    Kang HJ; Lee JM; Yoon JH; Han JK
    Korean J Radiol; 2021 Mar; 22(3):354-365. PubMed ID: 33236540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images.
    Wang YC; Chou CT; Lin CP; Chen YL; Chen YF; Chen RC
    PLoS One; 2017; 12(3):e0174594. PubMed ID: 28355258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma.
    Iwamoto T; Imai Y; Kogita S; Igura T; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Seki Y; Ohashi H; Fujita N; Kudo M; Takehara T
    Dig Dis; 2016; 34(6):679-686. PubMed ID: 27750237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis.
    Zhou S; Wang S; Xiang J; Han Z; Wang W; Zhang S; Opara NC; Ju S; Cui Y; Wang YC
    Abdom Radiol (NY); 2024 Feb; 49(2):471-483. PubMed ID: 38200213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
    Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
    Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma.
    Fan Y; Yu Y; Hu M; Wang X; Du M; Guo L; Hu C
    Br J Radiol; 2021 Mar; 94(1119):20200950. PubMed ID: 33417489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining the Arterial Phase of Contrast-Enhanced Ultrasonography, Gadoxetic Acid-Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging in the Diagnosis of Hepatic Nodules ≤20 mm in Patients with Cirrhosis.
    Zhou Y; Jing X; Zhang X; Ding J; Wang Y; Zhou H; Zhang Q; Chen Y; Yue W
    Ultrasound Med Biol; 2019 Mar; 45(3):693-701. PubMed ID: 30606633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.